

**From:** [Evyonne Smith](#)  
**To:** [Pharmacy Consultation](#)  
**Subject:** Guidelines on compounding of medicines  
**Date:** Tuesday, 29 March 2016 5:31:07 PM  
**Attachments:** [image001.png](#)  
[image002.png](#)  
[image003.png](#)  
[image004.png](#)  
[image005.png](#)

---

I am replying to the request for comments on the above document.

I agree with this document and support the level of detail it provides to pharmacies to ensure they are complying with high standards of sterile compounding. It does greatly reduce the expiry for room temperature products to 48 or 30hrs which may have a significant impact on hospital pharmacies especially those who aren't currently funded for weekend compounding and need to give chemotherapy over the weekends to patients. I don't support the expiry of 14 days for low risk items especially if there is no auditing of compliance with these guidelines.

I have one question about the use of Closed Transfer Device Systems. There is no guidance as to when you use CTDS how it affects the Risk Level of the products. If you use PhaSeal can you give products a 'lower' risk rating?

For example if you are using PhaSeal, a vial is only punctured once by the needle on the PhaSeal Adaptor. However if you are reconstituting a vial or using 1 vial for multiple doses (which happens quite often in paediatrics) you may need 3 or 4 punctures of the phaSeal Adaptor however this is only still 1 puncture of the vial bung? Does this still allow you to give this product a Low Risk Level? Some guidance around this would be appreciated.

Regards

**Evyonne Smith**

Pharmacist Advanced - Clinical Trials and Oncology (Mon-Tues)  
Pharmacy Department  
Children's Health Queensland Hospital and Health Service



W: [www.childrens.health.qld.gov.au](http://www.childrens.health.qld.gov.au)

\*\*\*\*\*

This email, including any attachments sent with it, is confidential and for the sole use of the intended recipient(s). This confidentiality is not waived or lost, if you receive it and you are not the intended recipient(s), or if it is transmitted/received in error.

Any unauthorised use, alteration, disclosure, distribution or review of this email is strictly prohibited. The information contained in this email, including any attachment sent with it, may be subject to a statutory duty of confidentiality if it relates to health service matters.

If you are not the intended recipient(s), or if you have received this email in error, you are asked to immediately notify the sender by telephone collect on Australia +61 1800 198 175 or by return email. You should also delete this email, and any copies, from your computer system network and destroy any hard copies produced.

If not an intended recipient of this email, you must not copy, distribute or take any action(s) that relies on it; any form of disclosure, modification, distribution and/or publication of this email is also prohibited.

Although Queensland Health takes all reasonable steps to ensure this email does not contain malicious software, Queensland Health does not accept responsibility for the consequences if any person's computer inadvertently suffers any disruption to services, loss of information, harm or

is infected with a virus, other malicious computer programme or code that may occur as a consequence of receiving this email.

Unless stated otherwise, this email represents only the views of the sender and not the views of the Queensland Government.

\*\*\*\*\*